Abstract 1522
Background
Cancer associated fibroblasts (CAFs) can help tumours evade immune-surveillance by affecting the immune cell infiltrate, mainly via secretion of cytokines and chemokines. CAFs phenotype and spatial relationship to cancer cells alter the kind of cytokines and chemokines they secrete. In Squamous cell carcinoma (SCC), cancer-associated fibroblasts can trigger a Type I Interferon when in direct cell-cell contact with cancer cells.
Methods
Bioinformatics: we used publicly available RNAseq data from The Cancer Genome Atlas (TCGA) for Head and Neck Squamous Cell Carcinoma (HNSCC 518 tumours. [http://firebrowse.org/]) . Using the RSEM normalized gene expression, we divided tumours according to the expression of CAF markers not expressed in cancer cells (FAP, Thy-1, s100a4and PDGFRb). We used CIBERSORT to estimate the abundance of immune cells in the tumours. In vitro assays: we used A431 (human SCC cell line) and CAFs extracted from a human tumour in our lab. We cultured them in either direct cell-to-cell contact or using a transwell. We treated the A431 with AZD6738 (ATR inhibitor), 5-aza-2′-deoxycytidine and cisplatin. We analysed mRNA expression of different interferon response genes by qRT-PCR.
Results
To explore the relevance of CAF influence in the immune infiltrate we analysed RNA seq data from HNSCC in TCGA. Tumours with higher expression of FAP and PDGFRb showed a higher proportion of infiltrating M0 and M2 macrophages. Tumours with lower expression of FAP and PDGFRb had higher proportions of activated dendritic cells and CD8 positive lymphocytes. In an “in vitro” human SCC model, heterotypic cancer cell-CAF contact leads to transfer of double stranded DNA from the cancer cell to the fibroblasts. This interaction triggers cGAS-STING mediated production of Interferon b (IFNb) in the CAFs. We treated cancer cells with drugs that generate genomic damage i.e. AZD6738, 5-aza and cisplatin. Treatment with these drugs increased the signal initiated by IFNb.
Conclusions
CAF subtypes abundance correlates with an immunosuppressive tumour microenvironment in HNSCC. Drugs currently used for routine treatment or in clinical trials for HNSCC modulate cytokine and chemokine production by CAFs in an “in vitro” model.
Clinical trial identification
Legal entity responsible for the study
The Francis Crick Institute.
Funding
Cancer Research UK.
Editorial Acknowledgement
Disclosure
K. Harrington: Consultancy (Includes expert testimony): Amgen, AstraZeneca, BMS, Merck, MSD, Pfizer; Research funding: AstraZeneca, MSD; Honoraria: Amgen, AstraZeneca, BMS, Merck, MSD, Pfizer, Replimune; Speakers' bureau: Amgen, AstraZeneca, BMS, Merck, MSD, Pfizer; Membership on any entity’s Board of Directors or advisory committees: Amgen, AstraZeneca, BMS, Merck, MSD, Pfizer, Replimune (Scientific advisory board memberships). All other authors have declared no conflicts of interest.
Resources from the same session
4679 - Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase 2 trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
Presenter: Chung-Han Lee
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5379 - End-to-end learning to predict survival in patients with gastric cancer using convolutional neural networks
Presenter: Armin Meier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5394 - Detection of Targetable Kinase Fusions in 7260 patients in an integrated Cancer System
Presenter: Ankur Parikh
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5884 - Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies
Presenter: Yali Li
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5912 - SET overexpression promotes colorectal cancer progression and determines poor outcome in patients with localized disease.
Presenter: Blanca Torrejón
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1168 - The functional MDM4 genetic variant in advanced lung adenocarcinoma patients treated with EGFR-TKIs
Presenter: Nasha Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3071 - PD-L1 expression on pre-treatment circulating tumour cells, but not serum VEGF, is predictive of response to pembrolizumab in melanoma
Presenter: Muhammad Khattak
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4062 - Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer
Presenter: Yu-Zhen Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4801 - A diagnostic model for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multi-center study
Presenter: Tian Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4874 - Dissecting Gastric Cancer biology and how and when to use immunotherapy
Presenter: Meghna Das Thakur
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract